Comparative Pharmacology
Head-to-head clinical analysis: ACHROMYCIN versus DECLOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACHROMYCIN versus DECLOMYCIN.
ACHROMYCIN vs DECLOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
None Documented
None Documented
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic